Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0223

Advisory board · Dr. Ximena Jensen

16 May 2026 · Phone · Dr. Ximena Jensen, Hospital La Paz · MSL Luis Ortega · Lumeva

ReviewedManualENG-0223—

Capture insight from this engagement

Location: Hospital La Paz
Therapeutic area: Neurology
Country: Spain
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Chronic migraine data
Medication-overuse headache
Real-world persistence

Scientific content used

CGRP class review
Chronic migraine scientific platform

Questions raised

What is the persistence rate at 18 months in real-world cohorts?

Notes

Advisory board with primary care physician at Hospital La Paz. Discussed chronic migraine data, medication-overuse headache, real-world persistence.

Insights captured (1)

Capture insight

INS-0018Medium
Chronic migraine data
Chronic migraine data: gap in current materials reported by primary care physician (ES).
Archived

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Connect with Clinical Development

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 5
Depth of exchange: 2
Actionability: 2

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0223

Audit history (0)

All create, update and approval events for this record

No audit events in sample data